Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

NCT05076695 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor-positive Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: trastuzumab
DRUG: pyrotinib
DRUG: fulvestrant

Sponsor

Fudan University